MedTrace Logo

Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis

NCT01433497 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 656

Last updated 2020-04-08

No results posted yet for this study

Summary

The purpose of this study is to compare the safety and efficacy of masitinib 6 mg/kg/day versus placebo in the treatment of patients with primary progressive multiple sclerosis or relapse-free secondary progressive multiple sclerosis.

Conditions

  • Multiple Sclerosis, Secondary Progressive
  • Multiple Sclerosis, Primary Progressive
  • Multiple Sclerosis, Relapse Free

Interventions

DRUG

Masitinib

DRUG

Placebo

Sponsors & Collaborators

  • AB Science

    lead INDUSTRY

Principal Investigators

  • Patrick Vermersch, MD, PhD · Hôpital Salengro, Lille, France

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2019-09-30
Completion
2020-02-29

Countries

  • Bulgaria
  • France
  • Germany
  • Greece
  • Poland
  • Romania
  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01433497 on ClinicalTrials.gov